The 19th Annual Intercompany Long-Term Care Insurance Conference March 24-27, 2019 - Sheraton Grand Chicago - Chicago, IL

Managing Alzheimer’s Disease &

Understanding the Latest in Alzheimer’s Research

This   two   part   session   will   begin   with   Managing   Alzheimer’s   Disease:   Resources   and   Support   for   All   Stages   of   the Disease.   This   topic   will   include   facts   and   figures   on   the   financial   as   well   as   physical   and   emotional   impacts   of Alzheimer’s   and   dementia   on   the   U.S.   and   families.   The   session   explores   the   benefits   of   early   detection,   how   to address   a   diagnosis   of   Alzheimer’s   disease,   stages   of   the   disease   and   will   provide   best   practices   for   families   when planning   and/or   dealing   with   the   disease.   Most   importantly,   the   various   programs   and   services   of   the   Alzheimer’s Association   available   to   help   individuals   will   be   reviewed.   Presented   by   Ruth   Kolb   Drew,   Director   of   Information   and Support Services at the Alzheimer's Association. (75 minute session) Part   two   will   cover   Understanding   the   Latest   in   Alzheimer’s   Research.   Every   week   there   is   something   in   the   news about    Alzheimer’s    research,    treatments    or    prevention.    Join    James    A.    Hendrix,    PhD,    Director,    Global    Science Initiatives   at   the   Alzheimer's   Association   to   hear   the   latest   in   what   is   real   and   promising   in   the   fight   against Alzheimer’s. (75 minute session) Join us Wednesday, March 21st from 9am-12pm for this great session! Ruth   Drew,   is   the   Director   of   Information   and   Support   Services   at   the   home   office of   the   Alzheimer's   Association   in   Chicago,   where   she   leads   the   work   of:   •   The National   Alzheimer’s   Association   24-hour   Helpline,   which   offers   information   and counseling    to    over    300,000    callers    each    year,    in    cooperation    with    78    chapters across   the   country.   The   Helpline   assists   people   affected   by   Alzheimer's   disease, their   family   members   and   caregivers.   Drew   authored   and   directs   a   5-year,   $4.9 million   grant   from   the   Administration   on   Community   Living   which   helps   fund   the Helpline.   •   The   Green-Field   Library,   the   primary   dementia-focused   library   in   the   US. Drew   joined   the   Alzheimer’s   Association   in   2004   and   served   as   Program   Director   at a   chapter   before   moving   to   the   national   office   in   2010.   She   led   the   development   of family    education    programs    and    online    resources    used    across    the    country    to increase   awareness,   information   and   support   to   all   affected.   She   is   a   licensed   counselor   with   a   master’s   degree   in Counseling   Psychology   and   experience   in   inpatient   and   agency   settings.   She   has   presented   at   many   national   and regional   conferences,   written   and   directed   numerous   programs   and   grant   projects,   and   educated   thousands   of family   caregivers   and   professionals   concerning   caring   for   people   with   Alzheimer’s   and   other   dementias.   Drew   has   a personal   interest   in   the   work   of   the   Alzheimer’s   Association   because   her   father   has   the   disease,   and   she   is   honored to help other families impacted by Alzheimer’s. James   A.   Hendrix,   Ph.D.,   is   director,   global   science   initiatives,   at   the   Alzheimer’s Association.    As    a    member    of    the    Medical    and    Scientific    Relations    Division,    he provides    leadership    on    specific    domestic    and    international    efforts    focused    on advancing   the   division’s   science   agenda.   A   critical   element   of   his   role   is   to   manage industry    consortia    such    as    the    Alzheimer’s    Association    Research    Roundtable (AARR);   lead   the   Global   Biomarker   Standardization   Consortium;   manage   and   direct future   meeting   efforts   and   output;   and   assist   with   the   coordination   of   the   $100 million   dollar   Imaging   Dementia-Evidence   for   Amyloid   Scanning   (IDEAS)   Study   on the   clinical   usefulness   of   amyloid   PET   imaging.   Dr.   Hendrix   received   his   Ph.D.   and   a postdoctoral     fellowship     from     Colorado     State     University.     Before     joining     the Alzheimer’s   Association,   Dr.   Hendrix   was   a   pharmaceutical   scientist   with   a   focus   on drug   discovery   for   CNS   diseases.   Dr.   Hendrix   spent   18   years   working   at   Sanofi-Aventis   and   predecessor   companies, where   he   rose   to   level   of   senior   director,   U.S.   site   head   for   CNS   research.   He   also   spent   two   years   working   in   the biotech   industry   with   various   companies,   including   Oligomerix,   which   is   focused   on   tau   for   the   treatment   of Alzheimer’s disease.
© ILTCI Conference 2018-19 - All Rights Reserved.
The 19th Annual Intercompany Long-Term Care Insurance Conference March 24-27, 2019 - Sheraton Grand Chicago - Chicago, IL

Managing Alzheimer’s Disease &

Understanding the Latest in

Alzheimer’s Research

This   two   part   session   will   begin   with   Managing   Alzheimer’s   Disease: Resources   and   Support   for   All   Stages   of   the   Disease.   This   topic   will include    facts    and    figures    on    the    financial    as    well    as    physical    and emotional    impacts    of    Alzheimer’s    and    dementia    on    the    U.S.    and families.   The   session   explores   the   benefits   of   early   detection,   how   to address   a   diagnosis   of   Alzheimer’s   disease,   stages   of   the   disease   and will   provide   best   practices   for   families   when   planning   and/or   dealing with   the   disease.   Most   importantly,   the   various   programs   and   services of    the    Alzheimer’s    Association    available    to    help    individuals    will    be reviewed.   Presented   by   Ruth   Kolb   Drew,   Director   of   Information   and Support Services at the Alzheimer's Association. (75 minute session) Part   two   will   cover   Understanding   the   Latest   in   Alzheimer’s   Research. Every   week   there   is   something   in   the   news   about   Alzheimer’s   research, treatments   or   prevention.   Join   James   A.   Hendrix,   PhD,   Director,   Global Science   Initiatives   at   the   Alzheimer's   Association   to   hear   the   latest   in what   is   real   and   promising   in   the   fight   against   Alzheimer’s.   (75   minute session) Join   us   Wednesday,   March   21st   from   9am-12pm   for   this great session! Ruth   Drew,   is   the   Director   of   Information   and   Support   Services   at   the home   office   of   the   Alzheimer's   Association   in   Chicago,   where   she   leads the   work   of:   •   The   National   Alzheimer’s   Association   24-hour   Helpline, which   offers   information   and   counseling   to   over   300,000   callers   each year,   in   cooperation   with   78   chapters   across   the   country.   The   Helpline assists   people   affected   by   Alzheimer's   disease,   their   family   members and   caregivers.   Drew   authored   and   directs   a   5-year,   $4.9   million   grant from   the   Administration   on   Community   Living   which   helps   fund   the Helpline.    •    The    Green-Field    Library,    the    primary    dementia-focused library   in   the   US.   Drew   joined   the   Alzheimer’s   Association   in   2004   and served   as   Program   Director   at   a   chapter   before   moving   to   the   national office   in   2010.   She   led   the   development   of   family   education   programs and   online   resources   used   across   the   country   to   increase   awareness, information   and   support   to   all   affected.   She   is   a   licensed   counselor with   a   master’s   degree   in   Counseling   Psychology   and   experience   in inpatient   and   agency   settings.   She   has   presented   at   many   national   and regional   conferences,   written   and   directed   numerous   programs   and grant    projects,    and    educated    thousands    of    family    caregivers    and professionals   concerning   caring   for   people   with   Alzheimer’s   and   other dementias.   Drew   has   a   personal   interest   in   the   work   of   the   Alzheimer’s Association   because   her   father   has   the   disease,   and   she   is   honored   to help other families impacted by Alzheimer’s. James   A.   Hendrix,   Ph.D.,   is   director,   global   science   initiatives,   at   the Alzheimer’s   Association.   As   a   member   of   the   Medical   and   Scientific Relations    Division,    he    provides    leadership    on    specific    domestic    and international    efforts    focused    on    advancing    the    division’s    science agenda.   A   critical   element   of   his   role   is   to   manage   industry   consortia such   as   the   Alzheimer’s   Association   Research   Roundtable   (AARR);   lead the   Global   Biomarker   Standardization   Consortium;   manage   and   direct future   meeting   efforts   and   output;   and   assist   with   the   coordination   of the     $100     million     dollar     Imaging     Dementia-Evidence     for     Amyloid Scanning    (IDEAS)    Study    on    the    clinical    usefulness    of    amyloid    PET imaging.   Dr.   Hendrix   received   his   Ph.D.   and   a   postdoctoral   fellowship from     Colorado     State     University.     Before     joining     the     Alzheimer’s Association,   Dr.   Hendrix   was   a   pharmaceutical   scientist   with   a   focus   on drug   discovery   for   CNS   diseases.   Dr.   Hendrix   spent   18   years   working   at Sanofi-Aventis   and   predecessor   companies,   where   he   rose   to   level   of senior   director,   U.S.   site   head   for   CNS   research.   He   also   spent   two years     working     in     the     biotech     industry     with     various     companies, including    Oligomerix,    which    is    focused    on    tau    for    the    treatment    of Alzheimer’s disease.